Lead Sponsor

Exelixis

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

•Body weight must be ≥ 50 kg and \< 130 kg with a BMI ≤ 38.0 (kg/m2).
•Must use acceptable form of birth control during the course of the study and for 3 months following the single dose of study drug.
•Female subjects of childbearing potential must have a negative pregnancy test at screening and check-in.
•Negative test for HIV; hepatitis A, B, and C.
•Must have adequate vital sign reads at screening and check-in.
•Must be able to comply with dietary and fluid restrictions required for the study.

•History of medical or surgical conditions that would interfere with GI absorption, distribution, metabolism, or excretion of the study drug.
•Recent clinical evidence of pancreatic injury.
•Recent use of drugs known to significantly inhibit or induce P450 CYP3A4 enzymes.
•Previous diagnosis of malignancy.
•Unwilling to forgo use of any over-the-counter or non-prescription preparations.

Related studies

NCT06631261 · Bronchiectasis Adult, Healthy Controls Group - Age and Sex-matched

NCT07258836 · Neoplasms, Healthy

NCT07545590 · Healthy

NCT00090662 · Healthy Volunteer

NCT07059858 · Intellectual Disability, Healthy Subjects

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function